ISSN 1004-4140
CN 11-3017/P
| Citation: |
YANG N J, ZHOU P, REN J, et al. Relationship between Tumor Burden and Early Response Time and Radiation Dose after Intraoperative Radiotherapy for Unresectable Pancreatic Cancer[J]. CT Theory and Applications, 2023, 32(6): 783-791. DOI: 10.15953/j.ctta.2022.180. (in Chinese).
|
Objective: To investigate the correlation between changes in tumor burden and the dose of intraoperative radiation therapy (IORT) for unresectable pancreatic cancer within 60 days of treatment evaluated using imaging parameters. Methods: A total of 32 cases of unrespectable pancreatic cancer treated with IORT at the Sichuan Cancer Hospital from April 2017 to July 2020 were retrospectively included. The imaging parameters of the tumor were recorded 7 days before IORT and 60 days after IORT: the longest axis (LA), shortest axis (SA), largest cross-sectional area (A), absolute value changes of each parameter (Δ), and change rate (Δ%). Different tumor load groups (shrinking/stabilizing/increasing) were differentiated, and the relationship between each parameter, IORT radiation dose, and tumor response time was analyzed. Results: The LA of unresectable pancreatic cancer after IORT was lower than that before IORT, with significant differences observed. The SA and A values of unresectable pancreatic cancer after IORT were lower than those before IORT, with no statistical significance observed. Based on ΔLA of the pancreatic tumor, the three groups, shrinkage, stability, and enlargement, were divided, with a corresponding tumor response time of (39.57±11.77) d, (38.08±12.87) d, (41.17±42) d, respectively. There were no significant differences in LA, SA, and A among the three groups before IORT, while significant differences were observed in LA, SA, and A after IORT. The ΔLA of the three groups was statistically significant before and after IORT. There was a moderate negative correlation between ΔLA and IORT dose levels in unrespectable pancreatic cancer (r=−0.47,). There was a moderate and high correlation between ΔLA and IORT dose in the stable group and ΔA and IORT dose in the enlargement group, respectively (r=0.66 vs. 0.90). There was no significant correlation between the response time and imaging parameters in these groups, except for a moderate negative correlation between ΔSA and response time in the stability group (r=−0.68). Conclusion: ΔLA can be used to evaluate changes in tumor load within 60 days of IORT for unresectable pancreatic cancer. The efficacy of pancreatic cancer could be correlated with the IORT irradiation dose, whereas the tumor burden could not be affected by the tumor response time.
| [1] |
ELASHWAH A, ALSUHAIBANI A, ALZAHRANI A, et al. The use of intraoperative radiation therapy (IORT) in multimodal management of cancer patients: A single-institution experience[J]. The Journal of Gastrointestinal Cancer, 2022. doi: 10.1007/s12029-021-00786-9
|
| [2] |
World Health Organization. World health organization handbook for reporting results of cancer treatment[S]. Geneva: World Health Organization, 1979.
|
| [3] |
CHALIAN H, TÖRE H G, HOROWITZ J M, et al. Radiologic assessment of response to therapy: Comparison of RECIST versions 1.1 and 1.0[J]. Radiographics, 2011, 31(7): 2093−2105. doi: 10.1148/rg.317115050
|
| [4] |
JAGODA P, FLECKENSTEIN J, SONNHOFF M, et al. Diffusion-weighted MRI improves response assessment after definitive radiotherapy in patients with NSCLC[J]. Cancer Imaging, 2021, 21(1): 15.
|
| [5] |
闵旭红, 宋奇隆, 余永强, 等. 三维CT定量联合定性参数的logistic回归模型对纯磨玻璃结节侵袭程度的临床预测价值[J]. 中华放射学杂志, 2021,55(1): 34−39. doi: 10.3760/cma.j.cn112149-20200318-00416
MIN X H, SONG Q L, YU Y Q, et al. The clinical value of the logistic regression model with a combination of three-dimensional CT quantitative and qualitative parameters in predicting the invasiveness of pure ground glass nodules[J]. Chinese Journal of Radiology, 2021, 55(1): 34−39. (in Chinese). doi: 10.3760/cma.j.cn112149-20200318-00416
|
| [6] |
NISHINO M, GIOBBIE‑HURDER A, GARGANO M, et al. Developing a common language for tumor response to immunotherapy: Immune‑related response criteria using unidimensional measurements[J]. Clinic Cancer Research, 2013, 19(14): 3936‑3943.
|
| [7] |
CHUONG M D, HAYMAN T J, PATEL M R, et al. Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer[J]. Gastrointestinal Cancer Research, 2011, 4(4): 128−134.
|
| [8] |
WELSH J L, BODEKER K, FALLON E, et al. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma[J]. American Journal of Surgery, 2012, 204(5): 580−585. doi: 10.1016/j.amjsurg.2012.07.007
|
| [9] |
NISHIMURA A, OTSU H, ITOH I, et al. Response of pancreatic tumor to intraoperative radiotherapy: Medical imaging and pathologic system approach[J]. The Journal of Computed Tomography, 1987, 11(1): 5−15. doi: 10.1016/0149-936X(87)90026-9
|
| [10] |
KANAMORI S, NISHIMURA Y, KOKUBO M, et al. Tumor response and patterns of failure following intraoperative radiotherapy for unresectable pancreatic cancer: Evaluation by computed tomography[J]. Acta Oncologica, 1999, 38(2): 215−220. doi: 10.1080/028418699431645
|
| [11] |
吴莉莉, 许耀麟, 楼文晖. 放射治疗在胰腺癌治疗中的应用现状和展望[J]. 外科理论与实践, 2022,27(1): 25−29.
WU L L, XU Y L, LOU W H. Application and prospect of radiotherapy in pancreatic cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(1): 25−29. (in Chinese).
|
| [12] |
LIERMANN J, MUNTER M, NAUMANN P, et al. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial[J]. Clinical and Translational Radiation Oncology, 2022, 34: 15−22. doi: 10.1016/j.ctro.2022.03.003
|
| [13] |
HAMA Y, TATE E. High-dose planned adaptive intensity-modulated radiation therapy with simultaneous integrated boost for synchronous oligometastatic pancreatic cancer[J]. Cancer Investigation, 2022, 40(5): 437−441. doi: 10.1080/07357907.2022.2049287
|
| [14] |
COMITO T, COZZI L, CLERICI E, et al. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study[J]. Technology in Cancer Research and Treatment, 2017, 16(3): 295−301. doi: 10.1177/1533034616650778
|
| [15] |
WA K, KARASAWA K, ITO Y, et al. Intraoperative radiotherapy for resected pancreatic cancer: A multiinstitutional retrospective analysis of 210 patients[J]. International Journal of Radiation Oncology Biology Physics, 2010, 77: 734−742. doi: 10.1016/j.ijrobp.2009.09.010
|
| [16] |
SINDELAR W F, KINSELLA T J. Normal tissue tolerance to intraoperative radiotherapy[J]. Surgical Oncology Clinics of North America, 2003, 12: 925−942. doi: 10.1016/S1055-3207(03)00087-5
|
| [17] |
KIM J W, CHO Y, KIM H S, et al. A phase II study of intraoperative radiotherapy using a low-energy X-ray source for resectable pancreatic cancer: A study protocol[J]. BMC Surgery, 2019, 19(1): 31. doi: 10.1186/s12893-019-0492-x
|
| [18] |
CHO Y, KIM J W, KIM H S, et al. Intraoperative radiotherapy for resectable pancreatic cancer using a low-energy X-ray source: Postoperative complications and early outcomes[J]. Yonsei Medical Journal, 2022, 63(5): 405−412. doi: 10.3349/ymj.2022.63.5.405
|
| [19] |
MOHAPATRA D, DAS B, SURESH V, et al. Fluvastatin sensitizes pancreatic cancer cells toward radiation therapy and suppresses radiation- and/or TGF-β-induced tumor-associated fibrosis[J]. Laboratory Investigation, 2022, 102(3): 298−311. doi: 10.1038/s41374-021-00690-7
|
| [20] |
ZHANG Z, ZHANG H, SHI L, et al. Heterogeneous cancer-associated fibroblasts: A new perspective for understanding immunosuppression in pancreatic cancer[J]. Immunology, 2022, 167(1): 1-14. DOI: 10.1111/imm.13496.
|
Supported by: Beijing Renhe Information Technology Co. Ltd 
DownLoad: